StoneStable, Inc.
StoneStable uses silica to coat viruses and biologicals to improve gene transduction
- Stage Product In Development
- Industry Biotechnology
- Location Portland, OR, USA
- Currency USD
- Founded December 2014
- Employees 2
- Incorporation Type C-corp
- Website stonestable.com
Company Summary
StoneStable, Inc. is the silica-stabilization company. Our technology reversibly coats viral vectors, vaccines and other biologicals in silica. This process confers enhanced immune response, greater transduction efficiency and confers stability in widely varying environmental conditions. Currently we are focussing on applying our technology to cell and gene therapies.
Team
-
CSO and FounderProfessor of Biology, Portland State University
Affiliate Professor of Chemical Pharmacology and Biochemistry, OHSU
Co-Founder, Center for Life in Extreme Environments
Chair NASA Virus Focus Group
Co-Founder, StoneStable, Inc.
Published over 80 papers and book chapters
Co-inventor of StoneStable technology
Over 100 media appearances
Previously worked at Sandoz, now Novartis, and Genentech
Obtained over 6 million dollars in research grants -
CEOCEO Auxetics
Partner, BridgeWorks Capital, LLC
MS. MBA
Ex - Merrill and Nike
Advisors
-
Chief, Laboratory of Immunologic Monitoring, Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Center
Sandra ShotwellPresident and COO DesignMedix, Managing Partner, Alta Biomedical Group LLC, CEO Elex BiotechUnconfirmed
Dan SnyderUnconfirmed -
John BialUnconfirmed
Mark SlifkaUnconfirmed -
Giovanni MagniUnconfirmed
Kyle GeeUnconfirmed
Previous Investors
-
Elevate CapitalUnconfirmed
ONAMIUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.